Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of MoonLake Immunotherapeutics during the specified Class Period of the upcoming lead plaintiff deadline on December 15, 2025 [1]. Group 1: Class Action Details - Investors who bought MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][6]. - A lead plaintiff must file a motion with the Court by December 15, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [4]. Group 3: Case Allegations - The complaint alleges that during the Class Period, defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5].

NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of James Hardie Industries plc (NYSE: JHX) between May 20, 2025 through August 18, 2025, both dates inclusive (the “Class Period”) of the important December 23, 2025 lead plaintiff deadline. SO WHAT: If you purchased James Hardie common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency ...

ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TLXNovember 19, 2025 3:41 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 19, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates i ...

Core Insights - PAO Group, Inc. has launched the AI Positioning Program, a proprietary system aimed at enhancing attorneys' competitive edge in case preparation and litigation outcomes [1] Company Overview - PAO Group, Inc. is recognized as a leading innovator in legal advertising and technology, focusing on attorney performance enhancement [1] Product Details - The AI Positioning Program is designed to provide a significant boost in case performance, offering attorneys advanced tools for strategy and case preparation [1]

Core Viewpoint - Rosen Law Firm is encouraging investors of DexCom, Inc. to secure legal counsel before the December 29, 2025 deadline for a class action lawsuit related to securities purchased between July 26, 2024, and September 17, 2025 [2][3]. Group 1: Class Action Details - Investors who purchased DexCom securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which rendered them less reliable and posed health risks to users [6]. - The defendants are accused of making false statements regarding the reliability and functionality of the G6 and G7 devices, leading to increased regulatory scrutiny and potential financial harm [6]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [5]. - Rosen Law Firm has a history of successful settlements in securities class actions, having recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [5]. - The firm has been recognized for its leadership in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased CarMax, Inc. securities between June 20, 2025, and November 5, 2025, about the January 2, 2026, deadline to become lead plaintiffs in a securities class action lawsuit [1][3]. Group 1: Class Action Details - Investors who bought CarMax securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must act by January 2, 2026, to serve as lead plaintiffs [3][5]. - The lawsuit alleges that CarMax's management made materially false and misleading statements regarding the company's growth prospects, which were overstated due to temporary market conditions [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in achieving significant settlements for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and recovering over $438 million for investors in 2019 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Synopsys, Inc. securities between December 4, 2024, and September 9, 2025, of the December 30, 2025, deadline to become lead plaintiffs in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Synopsys securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by December 30, 2025, to serve as lead plaintiff [2] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] Group 2: Case Allegations - The lawsuit alleges that Synopsys made materially false and misleading statements and failed to disclose adverse facts about its business and operations [4] - Specific claims include that Synopsys' focus on artificial intelligence customers was negatively impacting the economics of its Design IP business and that certain decisions were unlikely to yield intended results [4] - The lawsuit asserts that these undisclosed issues had a material negative impact on financial results, leading to misleading positive statements about the company's prospects [4]

Core Viewpoint - Rosen Law Firm is urging investors of Synopsys, Inc. to secure legal counsel before the December 30, 2025 deadline for a class action lawsuit related to securities purchased between December 4, 2024, and September 9, 2025 [2] Group 1: Class Action Details - Investors who purchased Synopsys securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 30, 2025 [4] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [5] Group 2: Case Allegations - The lawsuit alleges that Synopsys made materially false and misleading statements and failed to disclose adverse facts about its business and operations [6] - Specific claims include the negative impact of Synopsys' focus on artificial intelligence customers on its Design IP business, leading to poor financial results [6] - The lawsuit asserts that the misleading statements caused investors to suffer damages when the true information became public [6]

Core Viewpoint - A class action lawsuit has been filed against Primo Water Corporation and Primo Brands Corporation, alleging misrepresentation and failure to disclose key facts regarding the merger between the two companies, which led to investor losses during the specified Class Period [1][5]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of common stock of Primo Water Corporation from June 17, 2024, to November 8, 2024, and purchasers of Primo Brands Corporation from November 11, 2024, to November 6, 2025 [1]. - The lawsuit claims that the defendants made materially false and misleading statements about the merger's progress, leading investors to believe in accelerated growth and strong financial results [5]. Group 2: Legal Representation - Investors who purchased Primo Brands securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm is encouraging investors of Inspire Medical Systems, Inc. to secure legal counsel before the January 5, 2026 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [2][4]. Group 1: Class Action Details - The class period for the lawsuit is from August 6, 2024, to August 4, 2025, during which investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3][6]. - A class action lawsuit has already been filed, and investors wishing to serve as lead plaintiffs must act by January 5, 2026 [4][6]. Group 2: Allegations Against Inspire Medical - The lawsuit alleges that Inspire Medical misrepresented and failed to disclose critical information regarding the Inspire V sleep apnea device, including its actual market demand and the necessary steps for its launch [6]. - Defendants are accused of issuing materially false and misleading statements that led investors to believe in strong demand for the Inspire V device, resulting in investor damages when the true details became known [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [5]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [5].